QY Research Inc. (Global Market Report Research Publisher) announces the release of 2025 latest report “Ophthalmology AI Screening Software- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2020-2024) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Ophthalmology AI Screening Software market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for Ophthalmology AI Screening Software was estimated to be worth US$ 2032 million in 2025 and is projected to reach US$ 11313 million, growing at a CAGR of 28.2% from 2026 to 2032.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/5779499/ophthalmology-ai-screening-software
1. Ophthalmology AI Screening Software Market Summary
AI-powered ophthalmic screening software refers to medical software that uses artificial intelligence technology, especially deep learning algorithms, to automatically analyze eye images in order to achieve early detection of eye diseases, assist in diagnosis, and assess health risks. This type of software can quickly identify the characteristics of various eye diseases such as diabetic retinopathy, glaucoma, and age-related macular degeneration. Its core value lies in improving screening efficiency and consistency, assisting doctors in making judgments, and helping to extend high-quality ophthalmic diagnostic capabilities to resource-scarce areas.
According to the latest research report from QYResearch, in terms of market size, the global Ophthalmology AI Screening Software market size is projected to grow from USD 2 billion in 2025 to USD 11 billion by 2032, at a CAGR of 28.20% during the forecast period.
Ophthalmology AI Screening Software Industry Development Trends, Opportunities, Obstacles and Industry Barriers
Development Trends:
1. Evolution from Single-Disease Specialized Screening to Multi-Disease Comprehensive Screening Platforms: Early AI screening software primarily focused on single high-incidence diseases, such as diabetic retinopathy. The current mainstream trend is the development of comprehensive platforms capable of simultaneously detecting multiple eye diseases, such as identifying diabetic retinopathy, glaucoma, age-related macular degeneration, and cataracts in a single analysis. This “one scan, multiple screenings” model significantly improves screening efficiency, better meets the practical needs of public health and primary healthcare, and is becoming a core competitive advantage.
2. Integrated “Hardware + Software + Cloud Platform” Solutions Become the Delivery Standard: Pure software applications face deployment and compatibility challenges. Therefore, leading companies are actively collaborating deeply with manufacturers of hardware such as fundus cameras and OCT scanners, or developing their own solutions, to provide integrated hardware and software devices. Simultaneously, services are provided through cloud-based SaaS platforms, enabling continuous algorithm updates, centralized management of screening data, remote diagnostic support, and multi-center collaboration. This model reduces the initial investment for medical institutions and facilitates large-scale deployment.
3. Deep Integration with Telemedicine and Primary Healthcare Systems, Extending Scenarios: The core value of ophthalmic AI screening lies in solving the problem of accessibility to medical resources. Its application scenarios are rapidly expanding from hospital ophthalmology clinics to community health centers, primary care clinics, pharmacies, and even corporate health checkups. By embedding it into telemedicine platforms, primary care physicians can easily complete examinations and upload results, with screening reports directly provided by higher-level hospitals or AI, building a tiered medical network of “primary care examination, higher-level diagnosis,” significantly expanding the market boundaries.
Development Opportunities:
1. Huge Unmet Needs and Increasingly Clear Public Health Policy Support: More than one billion people worldwide suffer from vision impairment, most of which can be prevented through early screening. However, there is a severe shortage of professional ophthalmologists. Health departments in various countries are increasingly emphasizing the inclusion of eye disease screening in national chronic disease management plans or basic public health programs, creating stable government procurement and large-scale procurement opportunities for AI screening software, transforming the market from an “optional” to a “must-have.”
2. Technological Advancements Expanding to Anterior Segment Diseases and New Home Self-Examination Scenarios: With improved algorithm capabilities, AI screening is expanding from primarily focusing on posterior segment diseases to anterior segment diseases. Simultaneously, low-cost self-examination solutions using smartphone lenses or simple home devices are emerging. This allows high-risk groups or residents in remote areas to achieve more frequent self-monitoring, potentially opening up a huge consumer health market.
3. Gradually Improving Payment Systems and Exploration of Diverse Commercialization Models: Although challenges remain, the payment environment is improving. Some countries and regions have begun to reimburse specific AI-assisted screening services. Business models are becoming increasingly diversified, including selling/leasing equipment to medical institutions, charging per screening session, partnering with insurance companies for risk management, and collaborating with pharmaceutical companies for patient recruitment and efficacy follow-up, making profit paths clearer.
Hindering Factors:
1. The “Last Mile” Challenge of Clinical Adoption: Workflow Integration and Physician Trust: Even with regulatory approval, the actual implementation of products in hospitals still faces obstacles. How to seamlessly integrate AI reports with hospital information systems, adapt to different physicians’ work habits, and establish referral pathways for patients testing positive are all complex issues. Furthermore, some physicians remain cautious about the reliability of AI, and building clinical trust requires long-term, high-quality real-world evidence.
2. Global Compliance Challenges Regarding Data Privacy, Security, and Algorithmic Fairness: Medical data is protected by strict regulations in various countries, and cross-border training and use of data face limitations. At the same time, the fairness of algorithms is a concern: models trained on single-ethnicity data may perform worse on other ethnic groups. Ensuring universal applicability across multiple global populations requires significant investment in collecting and labeling diverse datasets and undergoing corresponding regulatory review.
3. Market Fragmentation and Pressures on Business Model Sustainability: The global market is highly fragmented, consisting of countries and regions with different payment capabilities, healthcare systems, and regulatory requirements. Companies need to localize for different markets, incurring high costs. Furthermore, in regions with underdeveloped payment systems, demonstrating cost-effectiveness to payers and establishing a sustainable revenue cycle remains a core survival challenge for many startups.
Barriers:
1. Extremely high regulatory and clinical validation barriers: In major markets, this type of software is managed as a Class II or Class III medical device. Obtaining certification from the US FDA, EU CE MDR, or China NMPA requires completing prospective, multi-center clinical trials to demonstrate key indicators such as sensitivity and specificity. This process is lengthy, costing tens of millions of dollars, and carries a high risk of failure, constituting an absolute technological and capital barrier to entry.
2. High-quality data loop and algorithmic leadership barriers: Building and maintaining algorithmic leadership requires the continuous acquisition of large amounts of high-quality, accurately labeled cross-ethnic clinical imaging data. This necessitates establishing long-term exclusive or priority partnerships with top ophthalmology institutions, forming a closed loop of “data acquisition – algorithm training – clinical validation – performance improvement.” New entrants find it difficult to build such a data moat and algorithm iteration capabilities in a short period.
3. Ecosystem cooperation and channel barriers for cross-regional commercialization: Success is not solely based on technology. Commercialization on a global scale requires building a complex ecosystem of partnerships: this includes collaborations with local medical device distributors, negotiating power with health insurance payers, an understanding of local healthcare processes, and the ability to provide long-term operational and service support. This overlaps significantly with the existing channels of medical device giants, making it difficult for new brands to quickly penetrate the market.
The report provides a detailed analysis of the market size, growth potential, and key trends for each segment. Through detailed analysis, industry players can identify profit opportunities, develop strategies for specific customer segments, and allocate resources effectively.
The Ophthalmology AI Screening Software market is segmented as below:
By Company
Eyenuk, Inc.
DeepMind
Remidio
Retmarker
AEYE Health
RetinaLyze
Synapxe
Intelligent Retinal Imaging Systems
RetinAI
RetinaRisk
CSIRO
Airdoc
Silicon Intelligence
Zhiyuan Huitu
WeDoctor Group
VoxelCloud
Kangfuzi Health
Zhenhealth
Tencent Health
Segment by Type
On-premises
Cloud-based
Segment by Application
Hospital
Eye Clinic
Medical Research
Others
Each chapter of the report provides detailed information for readers to further understand the Ophthalmology AI Screening Software market:
Chapter 1: Introduces the report scope of the Ophthalmology AI Screening Software report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry. (2021-2032)
Chapter 2: Detailed analysis of Ophthalmology AI Screening Software manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc. (2021-2026)
Chapter 3: Provides the analysis of various Ophthalmology AI Screening Software market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments. (2021-2032)
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.(2021-2032)
Chapter 5: Sales, revenue of Ophthalmology AI Screening Software in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world..(2021-2032)
Chapter 6: Sales, revenue of Ophthalmology AI Screening Software in country level. It provides sigmate data by Type, and by Application for each country/region.(2021-2032)
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc. (2021-2026)
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Benefits of purchasing QYResearch report:
Competitive Analysis: QYResearch provides in-depth Ophthalmology AI Screening Software competitive analysis, including information on key company profiles, new entrants, acquisitions, mergers, large market shear, opportunities, and challenges. These analyses provide clients with a comprehensive understanding of market conditions and competitive dynamics, enabling them to develop effective market strategies and maintain their competitive edge.
Industry Analysis: QYResearch provides Ophthalmology AI Screening Software comprehensive industry data and trend analysis, including raw material analysis, market application analysis, product type analysis, market demand analysis, market supply analysis, downstream market analysis, and supply chain analysis.
and trend analysis. These analyses help clients understand the direction of industry development and make informed business decisions.
Market Size: QYResearch provides Ophthalmology AI Screening Software market size analysis, including capacity, production, sales, production value, price, cost, and profit analysis. This data helps clients understand market size and development potential, and is an important reference for business development.
Other relevant reports of QYResearch:
Global Ophthalmology AI Screening Software Market Outlook, In‑Depth Analysis & Forecast to 2032
Global Ophthalmology AI Screening Software Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
Global Ophthalmology AI Screening Software Market Research Report 2026
About Us：
QYResearch founded in California, USA in 2007, which is a leading global market research and consulting company. Our primary business include market research reports, custom reports, commissioned research, IPO consultancy, business plans, etc. With over 19 years of experience and a dedicated research team, we are well placed to provide useful information and data for your business, and we have established offices in 7 countries (include United States, Germany, Switzerland, Japan, Korea, China and India) and business partners in over 30 countries. We have provided industrial information services to more than 60,000 companies in over the world.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
Email: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
